VolitionRX (VNRX) Corporate presentation summary

Mission and strategic focus

• Aims to save lives and improve outcomes for people and animals globally, focusing on cancer and sepsis diagnostics.

• Operates as an IP powerhouse with 56 patent families and a team with hundreds of years of experience.

• Pursues a derisked R&D and commercial strategy, emphasizing licensing and partnerships.

Technology and product platform

• Specializes in epigenetics, measuring chromatin fragments and quantifying nucleosomes for disease detection.

• Offers low-cost, platform-agnostic diagnostic tests adaptable to various workflows, including point-of-care and automated formats.

• Asset-light model eliminates the need for proprietary machines, labs, or sales reps.

Commercialization and business model

• Employs a low capex, low opex model focused on commercial partnerships and out-licensing.

• Monetizes IP through upfront, milestone, and recurring revenue from licensing agreements.

• Targets partners with broad reach, large installed bases, and strong regulatory and marketing capabilities.